{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:45:18Z","timestamp":1789429518641,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jns.2024.123154","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T01:50:29Z","timestamp":1722390629000},"page":"123154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Worsening of myasthenic symptoms associated with statins"],"prefix":"10.1016","volume":"464","author":[{"given":"Takamichi","family":"Sugimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemori","family":"Yamawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori P.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Samukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Nagane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123154_bb0005","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2024.123154_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance \u2013 an attempt at a unified definition. Position paper from an international lipid expert panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.jns.2024.123154_bb0015","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the Statin Intolerance Panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.jns.2024.123154_bb0020","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, Aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jns.2024.123154_bb0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5551\/jat.50948","article-title":"Statin Intolerance Clinical Guide 2018","volume":"27","author":"Kajinami","year":"2020","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.jns.2024.123154_bb0030","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update","volume":"29","author":"Mancini","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.jns.2024.123154_bb0035","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1161\/CIRCULATIONAHA.114.013189","article-title":"Statin intolerance","volume":"131","author":"Fitchett","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2024.123154_bb0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-017-0259-7","article-title":"Management of statin intolerance in 2018: Still more questions than answers","volume":"18","author":"Toth","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.jns.2024.123154_bb0045","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jns.2024.123154_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.123154_bb0055","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: an update","volume":"10","author":"Sheikh","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jns.2024.123154_bb0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.md.0000209337.59874.aa","article-title":"Statin-associated myasthenia gravis: report of 4 cases and review of the literature","volume":"85","author":"Purvin","year":"2006","journal-title":"Medicine"},{"key":"10.1016\/j.jns.2024.123154_bb0065","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/mus.21074","article-title":"Statins may aggravate myasthenia gravis","volume":"38","author":"Oh","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2024.123154_bb0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1752-1947-4-61","article-title":"Statin-associated weakness in myasthenia gravis: a case report","volume":"4","author":"Keogh","year":"2010","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.jns.2024.123154_bb0075","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacl.2014.12.005","article-title":"Use of lipid-lowering medications in myasthenia gravis: a case report and literature review","volume":"9","author":"Ragbourne","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.jns.2024.123154_bb0080","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/mus.21072","article-title":"More evidence for the association between statins and myasthenia gravis","volume":"38","author":"de Sousa","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2024.123154_bb0085","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/mus.26637","article-title":"Statin-induced myasthenia: a disproportionality analysis of the WHO\u2019s VigiBase pharmacovigilance database","volume":"60","author":"Gras-Champel","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2024.123154_bb0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cen3.12731","article-title":"Japan MG registry: chronological surveys over 10 years","volume":"14","author":"Suzuki","year":"2023","journal-title":"Clin Exp Neuroimmunol."},{"key":"10.1016\/j.jns.2024.123154_bb0095","first-page":"16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America neurology","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123154_bb0100","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123154_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.687585","article-title":"Hydrophilic or lipophilic statins?","volume":"8","author":"Climent","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.jns.2024.123154_bb0110","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/MOL.0000000000000236","article-title":"Statin intolerance","volume":"26","author":"Laufs","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jns.2024.123154_bb0115","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.dmpk.2016.09.002","article-title":"A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients","volume":"31","author":"Sai","year":"2016","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jns.2024.123154_bb0120","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000416","article-title":"Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies: an observational study in Japan","volume":"94","author":"Watanabe","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.jns.2024.123154_bb0125","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/eurheartj\/ehac556","article-title":"Individualized therapy in statin intolerance: the key to success","volume":"44","author":"Banach","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jns.2024.123154_bb0130","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(02)09846-X","article-title":"Statins, fibrates, and ocular myasthenia","volume":"360","author":"Parmar","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2024.123154_bb0135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jocn.2013.11.009","article-title":"Statins can induce myasthenia gravis","volume":"21","author":"Gale","year":"2014","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jns.2024.123154_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.029","article-title":"Myotoxicity of statins: mechanism of action","volume":"175","author":"du Souich","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jns.2024.123154_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108788","article-title":"Cholesterol in myasthenia gravis","volume":"701","author":"Paz","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.jns.2024.123154_bb0150","first-page":"218","article-title":"Biochemical and clinical consequences of inhibiting coenzyme Q biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): a critical overview","volume":"15","author":"Bliznakov","year":"1998","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jns.2024.123154_bb0155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.RES.83.5.490","article-title":"3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture","volume":"83","author":"Guijarro","year":"1998","journal-title":"Circ. Res."},{"key":"10.1016\/j.jns.2024.123154_bb0160","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/mus.880170808","article-title":"Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors","volume":"17","author":"Sonoda","year":"1994","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2024.123154_bb0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","article-title":"The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease","volume":"420","author":"Youssef","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jns.2024.123154_bb0170","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1038\/sj.emboj.7601288","article-title":"Cholesterol and lipid microdomains stabilize the postsynapse at the neuromuscular junction","volume":"25","author":"Willmann","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.jns.2024.123154_bb0175","first-page":"427","article-title":"Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia","volume":"118","author":"Negevesky","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jns.2024.123154_bb0180","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1212\/01.WNL.0000145708.03876.C3","article-title":"Statin-associated exacerbation of myasthenia gravis","volume":"63","author":"Cartwright","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123154_bb0185","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1111\/j.1468-1331.2008.02234.x","article-title":"Ptosis, diplopia and statins: an association?","volume":"15","author":"Elsais","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2024.123154_bb0190","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/mus.25155","article-title":"Statins and myasthenia gravis","volume":"54","author":"Khalid","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2024.123154_bb0195","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jns.2024.123154_bb0200","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fnmol.2020.00156","article-title":"Pathomechanisms and clinical implications of myasthenic syndromes exacerbated and induced by medical treatments","volume":"13","author":"Krenn","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.jns.2024.123154_bb0205","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/dmd.30.9.1029","article-title":"Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element","volume":"30","author":"El-Sankary","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jns.2024.123154_bb0210","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","article-title":"PharmGKB summary: cyclosporine and tacrolimus pathways","volume":"23","author":"Barbarino","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.jns.2024.123154_bb0215","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jcsm.12960","article-title":"Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: a position paper from the international lipid expert panel (ILEP)","volume":"13","author":"Penson","year":"2022","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.jns.2024.123154_bb0220","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1060028019871891","article-title":"Clinical controversy in transplantation: tacrolimus versus cyclosporine in statin drug interactions","volume":"54","author":"Migliozzi","year":"2020","journal-title":"Ann. Pharmacother."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T21:20:32Z","timestamp":1724534432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24002892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":44,"alternative-id":["S0022510X24002892"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123154","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Worsening of myasthenic symptoms associated with statins","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123154"}}